The pharmaceutical industry’s long-term prospects look promising, given the ever-expanding market for quality drugs and therapies. Moreover, due to the inelastic demand for its products, the pharmaceutical industry generally sustains its profit margins, rendering companies in this sector less vulnerable to economic downturns.
In this context, an evaluation of Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), and AbbVie Inc. (ABBV) reveals that each of them is well-positioned to surpass the broader market performance this year.
